The Alliance for Regenerative Medicine 2019 Cell & Gene Meeting on the Mediterranean

WASHINGTON, DC – April 30, 2019

The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader advanced therapies sector, was pleased to host the inaugural 2019 Cell & Gene Meeting on the Mediterranean from April 23-25 in Barcelona, Spain.

Approximately 500 delegates attended the meeting, which featured expert-led panels, discussions and presentations, focusing on the key topics and issues facing the sector, including scientific, clinical and regulatory landscape, pricing and reimbursement as well as manufacturing. If you would like to view any panels or presentations, these will be posted for playback two weeks after the close of the conference at

Alongside the main conference schedule there were 50+ dedicated presentations by the leading publicly traded and privately held companies, over 800 one-on-one partnering meetings and exclusive networking opportunities.
To view videos recorded at the conference with ARM CEO Janet Lambert and other presenters and delegates, please follow this link.

Janet Lambert, CEO of ARM, commented: “The inaugural Meeting on the Mediterranean has been a resounding success and I would like to thank all of the speakers and participants for their contributions. This event highlighted the vibrancy of the cell and gene therapy community in Europe and was a platform that brought leading experts, companies, industry bodies, and regulators together to discuss the future of these potentially transformative therapies and how we can work together to make them available to patients.”

Speakers included:

  • Guido Rasi, Director General, European Medicines Agency (EMA)
  • Keith Thompson, CEO, Cell and Gene Therapy Catapult
  • Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
  • Dan Faga, Chief Business Officer, Spark Therapeutics
  • Alison Finger, Chief Commercial Officer, bluebird bio
  • Claire Foreman, Head of Acute Programs, National Health Service
  • Owen Marks, Country Lead, Rare Diseases, Pfizer
  • Pascal Touchon, SVP, Global Head of Cell and Gene Europe, Novartis
  • Luca Alberici, Ph.D., Chief Business Officer, MolMed
  • Etienne Jousseaume, Head of Market Access, Cell and Gene Europe, Novartis
  • Jason Meyenburg, Chief Commercial Officer, Orchard Therapeutics
  • Usman Azam, President and CEO, Tmunity Therapeutics
  • Thomas Fellner, Ph.D., Head of Cell and Gene Therapy, Lonza
  • Joseph Tarnowski, Ph.D., SVP, Cell and Gene Therapy Platforms, Medicinal Science and Technology, R&D, GSK
  • Matthew Patterson, Chairman and CEO, Audentes Therapeutics; Chairman, Alliance for Regenerative Medicine
  • Amy DuRoss, Co-Founder and CEO, Vineti
  • Sven Kili, M.D., Principal, Sven Kili Consulting
  • Christopher Vann, Chief Operating Officer, Autolus Therapeutics
  • Rogerio Vivaldi, M.D., President and CEO, Sigilon Therapeutics
  • Ian Hudson, M.D., Chief Executive, Medicines and Healthcare Products Regulatory Agency
  • Katsuaki Ura, Deputy Director, Office of International Regulatory Affairs, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare

2019 presenting companies included: 3Scan; Adaptimmune; AGTC; Akron Biotech; Andalusian Initiative for Advanced Therapies; Aspect Biosystems; Audentes Therapeutics; Avectas; Axovant Gene Therapies; Biostage; bluebird bio; BlueRock Therapeutics; B-MoGen Biotechnologies; Bone Therapeutics; Caribou Biosciences; CEVEC Pharmaceuticals; Chimeric Therapeutics; Cryoport; Cynata Therapeutics; DiscGenics; FloDesign Sonics; FUJIFILM Cellular Dynamics; Genethon; Giner Life Sciences; Healios; Invitrx Therapeutics; Iovance Biotherapeutics; Kiadis Pharma; LogicBio Therapeutics; MaxCyte; MolMed; NAVAN Technologies; Novadip Biosciences; Orchard Therapeutics; Organovo; ORIG3N; Oxford Biomedica; panCELLa; PDC*line Pharma; PolarityTE; Promethera Biosciences; REGENXBIO; ReNeuron; Rexgenero; Sangamo Therapeutics; Sigilon Therapeutics; Spark Therapeutics; Terumo BCT; TikoMed; T-knife; Tmunity Therapeutics; uniQure; VERIGRAFT; Vivet Therapeutics; and Zelluna Immunotherapy.

Press enquiries

For more information about the conference or media requests, please contact Lyndsey Scull at or Matthew Neal from Consilium Strategic Communications at

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. Founded in 2009, ARM works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its 330+ member organizations worldwide. ARM represents the interests of therapeutic developers, academic research institutions, major medical centres, investors, and patient groups that comprise the broader regenerative medicine community and is the prominent international advocacy organization in this field.

ARM has 70+ members across 15 countries in Europe. ARM aims to work closely with European stakeholders, leveraging its membership to create a supportive commercial and regulatory environment to create better conditions for the development and commercialization of ATMPs in Europe; develop strong stakeholder support around proposed solutions to improve patient access to ATMPs; promote clear, predictable and efficient regulatory framework across Europe; and promote international convergence of key regulations and guidances.